Brokerages Expect Corvus Pharmaceuticals Inc (CRVS) Will Post Earnings of -$0.71 Per Share

Brokerages expect Corvus Pharmaceuticals Inc (NASDAQ:CRVS) to announce ($0.71) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Corvus Pharmaceuticals’ earnings. Corvus Pharmaceuticals posted earnings of ($0.79) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 10.1%. The business is scheduled to issue its next earnings results on Thursday, May 3rd.

According to Zacks, analysts expect that Corvus Pharmaceuticals will report full-year earnings of ($3.16) per share for the current fiscal year, with EPS estimates ranging from ($3.22) to ($3.09). For the next fiscal year, analysts forecast that the company will report earnings of ($2.93) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow Corvus Pharmaceuticals.

How to Become a New Pot Stock Millionaire

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its earnings results on Thursday, March 1st. The company reported ($0.58) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.76) by $0.18.

Several brokerages have commented on CRVS. ValuEngine downgraded Corvus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Zacks Investment Research lowered Corvus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, January 5th. Finally, Cowen reissued a “buy” rating on shares of Corvus Pharmaceuticals in a research report on Friday, March 2nd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. Corvus Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $20.25.

In other Corvus Pharmaceuticals news, CEO Richard A. Md Miller acquired 100,000 shares of the stock in a transaction dated Monday, March 12th. The stock was purchased at an average cost of $8.50 per share, with a total value of $850,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Adams Street Partners Llc acquired 588,235 shares of the stock in a transaction dated Monday, March 12th. The stock was acquired at an average cost of $8.50 per share, with a total value of $4,999,997.50. Following the completion of the transaction, the insider now owns 4,420,516 shares in the company, valued at approximately $37,574,386. The disclosure for this purchase can be found here. Company insiders own 46.40% of the company’s stock.

Several hedge funds have recently bought and sold shares of CRVS. BlackRock Inc. raised its position in shares of Corvus Pharmaceuticals by 76.0% in the 4th quarter. BlackRock Inc. now owns 669,657 shares of the company’s stock worth $6,937,000 after acquiring an additional 289,096 shares in the last quarter. Vanguard Group Inc. increased its position in Corvus Pharmaceuticals by 37.1% in the 2nd quarter. Vanguard Group Inc. now owns 373,512 shares of the company’s stock valued at $4,520,000 after buying an additional 101,013 shares in the last quarter. Northern Trust Corp increased its position in Corvus Pharmaceuticals by 97.6% in the 2nd quarter. Northern Trust Corp now owns 86,525 shares of the company’s stock valued at $1,047,000 after buying an additional 42,739 shares in the last quarter. Renaissance Technologies LLC increased its position in Corvus Pharmaceuticals by 20.5% in the 4th quarter. Renaissance Technologies LLC now owns 234,200 shares of the company’s stock valued at $2,426,000 after buying an additional 39,900 shares in the last quarter. Finally, Millennium Management LLC increased its position in Corvus Pharmaceuticals by 180.8% in the 4th quarter. Millennium Management LLC now owns 59,017 shares of the company’s stock valued at $611,000 after buying an additional 37,998 shares in the last quarter. 82.71% of the stock is owned by hedge funds and other institutional investors.

Shares of Corvus Pharmaceuticals stock traded down $0.14 on Monday, reaching $10.18. The company’s stock had a trading volume of 115,863 shares, compared to its average volume of 122,728. The firm has a market cap of $217.40, a P/E ratio of -3.72 and a beta of -1.50. Corvus Pharmaceuticals has a 52-week low of $7.42 and a 52-week high of $22.14.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.thelincolnianonline.com/2018/04/11/brokerages-expect-corvus-pharmaceuticals-inc-crvs-will-post-earnings-of-0-71-per-share.html.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.

Get a free copy of the Zacks research report on Corvus Pharmaceuticals (CRVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply